Mikel Arteta reveals genome sequencing results from Bupa partnership
Arsenal manager Mikel Arteta said he disclosed his results to make health part of the public conversation about leadership.
By Hana Yoshida · Markets Reporter
3 min read
Arsenal manager Mikel Arteta has publicly discussed Mikel Arteta genome sequencing results obtained through a partnership with healthcare company Bupa, saying health is central to his ability to lead his family and football club. He said he chose to disclose the experience because public discussion gives too much attention to professional success and too little to health, family and personal change.
Fortune reported that Arteta had his whole genome sequenced to understand more about how his body works and possible future health risks. The account was published in connection with a Bupa genomics campaign; no underlying test report, clinical assessment or test methodology was made public.
Why did Mikel Arteta go public about genome sequencing?
Arteta told Fortune that leaders need to look after themselves before they can lead others. He described health as the foundation of his energy, wellbeing and ability to manage daily work and connect with people.
He said he had a serious heart condition when he was young, and that the sequencing brought reassurance and helped him talk with his family about the future and healthy living. Arteta also said he wants to remain active with his children and on the training field as he gets older.
The disclosed findings were an increased likelihood of coeliac disease and a level of lactose intolerance, according to Fortune. Arteta said the results prompted him to pay closer attention to nutrition, sleep and other long-term health choices, and he said he feels healthier after making changes. Those are Arteta's personal accounts, rather than independently reported clinical outcomes.
What can genome sequencing results show?
Genome sequencing compares a person's genetic sequence with a reference sequence and can identify many genetic variants. The NIH-funded Clinical Sequencing Exploratory Research Consortium says most variants identified through exome or genome sequencing have little or no known effect on health, while others may be classified as benign, pathogenic or of uncertain significance.
That means results need clinical interpretation. The consortium's guide to genomic reports says laboratories use categories ranging from benign to pathogenic, including uncertain and likely pathogenic findings. Results can also include secondary findings unrelated to the original reason for testing.
The National Human Genome Research Institute says genome and exome sequencing cannot answer every medical question, do not cover all genetic material, and are not appropriate for every patient. A negative result does not necessarily rule out a genetic cause of disease, according to the institute.
Bupa says its service combines genomic information with clinical guidance and preventive care so people can understand their results and make informed health decisions. Its chief medical officer, Melvin Samsom, said Arteta could share his results with a doctor in the future. That is Bupa's description of its service, rather than an independent assessment of Arteta's individual findings.
This story draws on original reporting from Fortune.